Engineering cell-based therapies to interface robustly with host physiology

Kelly A. Schwarz, Joshua N Leonard*

*Corresponding author for this work

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Engineered cell-based therapies comprise a rapidly growing clinical technology for treating disease by leveraging the natural capabilities of cells, including migration, information transduction, and biosynthesis and secretion. There now exists a substantial portfolio of intracellular and extracellular sensors that enable bioengineers to program cells to execute defined responses to specific changes in state or environmental cues. As our capability to construct more sophisticated cellular programs increases, assessing and improving the degree to which cell-based therapies perform as desired in vivo will become an increasingly important consideration and opportunity for technological advancement. In this review, we seek to describe both current capabilities and potential needs for building cell-based therapies that interface with host physiology in a manner that is robust — a phrase we use in this context to describe the achievement of therapeutic efficacy across a range of patients and implementations. We first review the portfolio of sensors and outputs currently available for use in cell-based therapies by highlighting key advancements and current gaps. Then, we propose a conceptual framework for evaluating and pursuing robust clinical performance of engineered cell-based therapies.

Original languageEnglish (US)
Pages (from-to)55-65
Number of pages11
JournalAdvanced Drug Delivery Reviews
Volume105
DOIs
StatePublished - Oct 1 2016

    Fingerprint

Keywords

  • Biosensors
  • Cell-based therapies
  • Gene circuits
  • Mammalian synthetic biology

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this